T Man Pharmaceutical PCL
SET:TMAN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (4.6), the stock would be worth ฿-2.2 (117% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -27.2 | ฿12.9 |
0%
|
| 3-Year Average | 4.6 | ฿-2.2 |
-117%
|
| 5-Year Average | 4.6 | ฿-2.2 |
-117%
|
| Industry Average | 12.8 | ฿-6.08 |
-147%
|
| Country Average | 13.4 | ฿-6.39 |
-150%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| TH |
T
|
T Man Pharmaceutical PCL
SET:TMAN
|
5.2B THB | -27.2 | 9.9 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
291.1B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | -38 725.3 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
99.6B ZAR | 15.4 | 10.3 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
67.4B USD | -87 522.9 | 38 074.9 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
56B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
37.3B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
31.3B EUR | 69.7 | 173.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
35.6B USD | 45.5 | -3 268.5 | |
| US |
Q
|
Qnity Electronics Inc
NYSE:Q
|
29.5B USD | 0 | 0 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 8.8 |
| Median | 13.4 |
| 70th Percentile | 20 |
| Max | 1 747 |
Other Multiples
T Man Pharmaceutical PCL
Glance View
T Man Pharmaceutical PCL is a TH-based company operating in industry. The company is headquartered in Bangkok, Bangkok Metropolis. The company went IPO on 2024-10-22. T.Man Pharmaceutical Public Company Limited is engaged in purchasing, importing, manufacturing, original equipment manufacturing, distributing and exporting of modern medicines, traditional medicine, dietary supplements, and health care products for the healthcare industry with subsidiaries as manufacturers. Its segments include manufactured products under own brand, manufactured products under third parties’ brand and trading products. With a diverse range of manufacturing machinery, it can produce various types of pharmaceutical products, meeting the needs of every consumer. Its production capabilities include tablets, capsules, powders, liquids, and semisolids. The company offers capsule products, including both hard and soft capsules in various sizes, all made with imported, high-quality raw materials. Its product range covers a wide range of diseases and comes in various forms, including uncoated tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, and suppositories.
